CSIMarket Company Name, Ticker, Suppliers, else..
 
Citius Pharmaceuticals Inc   (NASDAQ: CTXR)
 

Citius Pharmaceuticals Inc's Suppliers Performance

CTXR's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
CTXR Costs vs Sales of Suppliers Growth Citius Pharmaceuticals Inc's cost of sales deteriorated by 0 % year on year, sequentially cost of sales grew by 49.55 % in Q3.

• More on CTXR Suppliers



Citius Pharmaceuticals Inc's cost of sales deteriorated by 0 % year on year, sequentially cost of sales grew by 49.55 % in Q3.

• More on CTXR Suppliers




Citius Pharmaceuticals Inc's Comment on Supply Chain


The company sources raw materials and supplies from multiple suppliers to mitigate the impact of losing any single source. It has contracted with established suppliers and manufacturers for active pharmaceutical ingredients, commercial supply, development, and packaging of LYMPHIR. Supply agreements have been secured directly or through Citius Oncology with third-party cGMP facilities compliant with FDA good manufacturing practices. Additional contracts through Citius Oncology cover testing, labeling, packaging, and distribution of LYMPHIR. The company states that all materials meet FDA specifications and that contract manufacturers have sufficient capacity to support increasing demand. The company notes that failure to raise additional capital could affect its contractual obligations and third-party support for commercialization.

Citius Pharmaceuticals Inc's Comment on Supply Chain


The company sources raw materials and supplies from multiple suppliers to mitigate the impact of losing any single source. It has contracted with established suppliers and manufacturers for active pharmaceutical ingredients, commercial supply, development, and packaging of LYMPHIR. Supply agreements have been secured directly or through Citius Oncology with third-party cGMP facilities compliant with FDA good manufacturing practices. Additional contracts through Citius Oncology cover testing, labeling, packaging, and distribution of LYMPHIR. The company states that all materials meet FDA specifications and that contract manufacturers have sufficient capacity to support increasing demand. The company notes that failure to raise additional capital could affect its contractual obligations and third-party support for commercialization.







CTXR's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Citius Pharmaceuticals Inc 15.14 0.00 -58.78 23
SUBTOTAL 0.00 0.00 0.00 -


Sources: Citius Pharmaceuticals Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Citius Pharmaceuticals Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.